Navigation Links
Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV,Activity

. Jenkins poster will be available for viewing at http://www.rigel.com after 11:00 a.m. PDT today.

Rigel's Rich Ligase Drug Discovery Program

Rigel is a leader in investigating and characterizing the ubiquitin ligase system for the discovery and development of potential new therapeutics. The company has initiated one of the industry's broadest efforts in working on the development of numerous ligase targets in oncology, inflammation, virology and metabolism. Rigel was one of the first companies to discover potent and highly selective small molecule inhibitors of ubiquitin ligases. Rigel has a broad- based platform in the enzymology and biology of ubiquitin ligases, which includes a large number of biochemical and cell-based assays to identify the specificity and selectivity of ligase targets. Rigel has an extensive patent portfolio covering the ligase area.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. We have achieved this goal since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof, and the potential ef
'"/>




Page: 1 2 3

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
7. Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
11. Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... VIEJO, Calif., Oct. 12, 2011 Avanir Pharmaceuticals, Inc. ... affect (PBA) prevalence data from stroke survivors will be ... Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in ... details about the data presentation at ACRM/ASNR Progress ...
... Good Start Genetics,™ Inc., an innovative molecular diagnostics ... screening, today announced that it will present results ... next-generation DNA sequencing platform at the Annual Meeting ...  ASRM will be held from October 15-19, 2011 ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference 2Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM) 2
(Date:4/23/2014)... Center researchers say clinical trials for a new ... are very promising. Patients treated with CPX-351, a ... are showing better responses than patients treated with ... "Acute myeloid leukemia is an aggressive blood cancer ... in older patients," explained Jeffrey Lancet, M.D., senior ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... half their concerns, so doctors should listen carefully, ... -- Older patients and surgeons don,t communicate effectively ... decision to have surgery can be particularly difficult ... School of Medicine study. , The researchers recorded ...
... Air-Pulse Autonomic Meditation Therapy is a non-denominational therapy that allows ... identity many feel when adopting ancient mind controlling meditative healings. ... ... 14, 2008 –- Dr. Ajrawat,s http://www.painmanagement.com/ [Air-Pulse Autonomic ...
... childhood asthma, but, when compared to girls, they are also ... have a decreased incidence of asthma in the post-pubertal years. ... asthma development, according to a prospective study that analyzed airway ... moderate asthma over a period of about nine years. , ...
... the past two decades, medication errors have dramatically increased. DecisionHealth, ... potentially harmful medication errors. , ... Gaithersburg, MD (PRWEB) ... Health Ledger,s recent drug overdose, increased dramatically over the past two ...
... Investigators from the Melbourne Center of the international Ludwig Institute ... reported that they have developed a test to predict whether ... metastatic Stage IV cancer and death. , More than ... has spread to the lymph nodes will typically have ...
... Investment to Close in September, Subject to Stockholder ... Potential Launch of MOXATAG(TM), GERMANTOWN, Md., Aug. ... a pharmaceutical company focused on,developing and commercializing novel ... the quarter ended June 30,2008., MiddleBrook reported ...
Cached Medicine News:Health News:Older Adults Reluctant to Question Surgical Treatment 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 3Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 4Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 5Health News:Asthma in boys may be just a phase, but for girls it may be there to stay 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 3Health News:Prototype test for predicting clinical outcome for melanoma patients 2Health News:Prototype test for predicting clinical outcome for melanoma patients 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 13
Infusion Cannula, 2.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
Medicine Products: